Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

Phase 2

Pfizer

Sitagliptin Phosphate